

Ref: MHL/Sec&Legal/2021-22/59

November 10, 2021

To,
Head, Listing Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers Dalal Street,
Mumbai - 400 001.

Head, Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1. G Block,
Bandra -Kurla Complex, Bandra (East),
Mumbai- 400051

Scrip Code: 542650

Scrip Symbol: METROPOLIS

Sub: Intimation of Press Release

Dear Sir/Madam,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed a Press Release as mentioned below:

'Metropolis Healthcare Limited continues the strong business momentum with recording Rs. 303 Crores revenue in Q2FY22.'

You are requested to take the above information on record.

Thanking You,

Yours Faithfully

For **Metropolis Healthcare Limited**

Simmi Singh Bisht
Head – Legal and Secretarial
ACS 23360
Encl. a/a

BLOOD TESTS • DIAGNOSTICS • WELLNESS

METROPOLIS
The Pathology Specialist

Metropolis Healthcare Limited

Registered & Corporate Office: 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400 030.
CIN: L73100MH2000PLC192798 Tel No.: 8422 801 801 Email: support@metropolisindia.com

Website: www.metropolisindia.com

Global Reference Laboratory: 4th Floor, Commercial Building-1A, Kohinoor Mall, Vidyavihar (W), Mumbai - 400 070.

Metropolis Healthcare Ltd. continues the strong business momentum with recording Rs. 303 Crs. revenue in Q2FY22

Non-Covid revenue grows 38% YoY to Rs. 260 Crs.

- Patient visits increased by 25% on YoY basis to 3.3 Mn.
- No. of tests increased by 29% on YoY basis to 6.2 Mn.
- Non-Covid Home Visits Revenue increased by 17% on YoY basis to Rs. 26 Crs.
- Revenue contribution from specialised tests (non-covid) increased to 43% in Q2FY22 from 39% in Q2FY21

Mumbai, November 10, 2021: Metropolis Healthcare Ltd. (NSE: METROPOLIS | BSE: 542650) - a leading diagnostic service provider - announced its unaudited consolidated financial results today for the second quarter (Q2FY22).

Q2FY22 Financial Highlights

30.8%

EBITDA Margin
(Before CSR & ESOP)

60%

Revenue share of B2C in
Focus Cities (Non-Covid)

Rs. 58.4 Crs.

Reported PAT

“We are pleased to share that we have continued the strong business momentum with recording robust revenue along with profitability during Q2FY22. This strong performance has been on the back of growth in sustainable non-covid revenue, increased patient visits & tests and increased contribution from specialized tests. With economy now strongly recovering from the pandemic, we expect our non-covid business to continue grow sustainably. Our recently acquired Hitech Diagnostics will further enable us to scale up our business, improve the B2C revenue contribution and increase our market penetration by catering to the value segment of the market.”

Ameera Shah, Promoter and Managing Director, Metropolis Healthcare Ltd.

ACCREDITATIONS FOR METROPOLIS

The Global Reference Laboratory of Metropolis holds accreditation from the College of American Pathologists (CAP) since 2005 which is the gold standard in accreditations in our industry, globally.

Our clinical laboratories hold one or more of CAP, NABL, KENAS, ILAC or APLAC accreditations.

(CAP: College of American Pathologists; NABL: National Accreditation Board for Testing and Calibration Laboratories; KENAS: Kenya Accreditation Service; ILAC: International Laboratory Accreditation Cooperation, APLAC: Asia Pacific Laboratory Accreditation Cooperation)

RECENT AWARDS AND ACCOLADES

Our MD, Ms. Ameera Shah has been featured among the Most Powerful Women in Business in 2021 by Fortune India for the fifth consecutive year.

Our MD, Ms. Ameera Shah won the prestigious Entrepreneur of the Year Award by EY in Lifesciences and Healthcare category

Metropolis Healthcare won the Leading Diagnostic Chain of the Year award at the Elets Diagnostics Leadership Summit, 2021

Metropolis Healthcare Ltd won the 2020 Indian Diagnostic Services Industry Company of the Year Award organised by Frost & Sullivan.

Metropolis Healthcare won the award for Outstanding Logistics Unit during Pandemic award in the Healthcare Category organised by Supply Chain and Logistics Excellence (SCALE) Awards

Metropolis won five different awards for its CSR Projects from different reputed CSR platforms.

Ms. Ameera Shah has been bestowed with Mumbai Ratna Award in recognition of her remarkable contributions to the community during the COVID 19 pandemic

Our MD, Ms. Ameera Shah has won the Woman of the Year award by the Ladies Wing of IMC Chamber of Commerce and Industry

Our CFO, Mr. Rakesh Agarwal was awarded at the 11th Annual CFO Awards for his exceptional contribution to the world of finance.

In INR Crs.	Q2FY22	Q2FY21
Revenue from Operations	302.6	288.4
EBIDTA before CSR & ESOP	93.2	94.9
Reported Profit After Tax	58.4	60.5
Reported PAT Margin (%)	19.3%	21.0%

About Metropolis: Metropolis Healthcare Ltd is a leading diagnostics company in India with a widespread presence across 20 states in India. Metropolis touches millions of lives each year by providing actionable health insights to patients and doctors. Metropolis offers a comprehensive range of 4000 plus tests and profiles that include advanced tests in diagnosis of cancer, neurological disorders, infectious diseases, and an array of genetic abnormalities. Metropolis' commitment to quality and accuracy in each test is reinforced by its consistent CAP proficiency score of more than 98% over the past decade, which places it amongst the top 1% laboratories worldwide for quality assurance. Metropolis philosophy rests on the pillars of technological superiority, a warm patient centric approach and reliable diagnostic reports. For more, please visit www.metropolisindia.com or click on [Twitter](#), [Facebook](#), or [LinkedIn](#).

Safe harbor statement

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For further details please contact:

Company: Metropolis Healthcare Ltd.

CIN -L73100MH2000PLC192798

Mr. Jeyasingh Balakrishnan – Head PR and Corporate Communications

jeyasingh.b@metropolisindia.com

www.metropolisindia.com

Investor Relations Advisors: Strategic Growth Advisors Pvt. Ltd.

CIN: U74140MH2010PTC204285

Mr. Shogun Jain / Mr. Shrenik Shah

shogun.jain@sgapl.net / shrenik.shah@sgapl.net